Close
Novotech
Jabsco PureFlo 21 Single Use

Alexion to Present at the Bank of America Merrill Lynch 2016 Health Care Conference

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Hypercon Technology Deal Signed between Halozyme and Vertex

Halozyme Therapeutics has entered into a global exclusive partnership...

Gilead Advances ADC Pipeline Expansion with $3B Tubulis Deal

Gilead Sciences has agreed to acquire Germany-based Tubulis in...

Neurocrine Nears $2.5bn Soleno Therapeutics Acquisition

Neurocrine Biosciences is close to securing a more than...
- Advertisement -

Alexion Pharmaceuticals, Inc announced that management will present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas on Tuesday, May 10, 2016 at 10:40 a.m., Pacific Time.

An audio webcast of the presentation will be available live. You can access the webcast at: http://ir.alexionpharm.com. An archived version of the remarks will also be available through the Company’s web site for a limited time following the conference.

 

Contact:

Alexion Pharmaceuticals, Inc.
Elena Ridloff, CFA
Vice President, Investor Relations
(203) 699-7722

 

Latest stories

Related stories

Hypercon Technology Deal Signed between Halozyme and Vertex

Halozyme Therapeutics has entered into a global exclusive partnership...

Gilead Advances ADC Pipeline Expansion with $3B Tubulis Deal

Gilead Sciences has agreed to acquire Germany-based Tubulis in...

Neurocrine Nears $2.5bn Soleno Therapeutics Acquisition

Neurocrine Biosciences is close to securing a more than...

Biogen to Acquire Apellis for $5.6 Billion in Major Deal

Biogen Inc. has agreed to acquire Apellis Pharmaceuticals Inc....

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »